US · KTTA
Pasithea Therapeutics Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Miami Beach, FL 33139
- Website
- pasithea.com
Price · as of 2024-12-31
$0.84
Market cap 6.56M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $24.00 | ||||
| 2022 | $9.68 | $306.98 | |||
| 2023 | $7.29 | ||||
| 2024 | $1.19 |
AI valuation
Our deep-learning model estimates Pasithea Therapeutics Corp.'s (KTTA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.84
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KTTA | Pasithea Therapeutics Cor… | $0.84 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| CYCN | Cyclerion Therapeutics, I… | $1.35 | 5.14M | — | +2,196,706% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| KALA | KALA BIO, Inc. | $0.38 | 8.33M | — | — | — | — | -1.01 | 3.16 | — | -0.49 | — | 3.16 | 0.00% | — | — | -388.29% | 599.82% | -69.12% | 2.62 | -7.09 | 3.11 | 3.02 | 0.46 | -5977.00% | — | 369.00% | -76.03% | -1.73 | 433.08% | 0.00% | 0.00% | 11.20% | -0.49 | -0.68 | — | -17.97 |
| PLRZ | Polyrizon Ltd. | $12.49 | 13.01M | — | — | — | — | -8.81 | 2.58 | — | -7.77 | — | 5.67 | 0.00% | — | — | -57.83% | -88.33% | -50.61% | 0.00 | -434.00 | 10.16 | 9.79 | 1.79 | — | — | 11359.00% | -8.43% | -4.39 | -77.82% | 0.00% | 0.00% | 20.20% | -8.49 | -9.64 | — | 29.76 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| VIVS | VivoSim Labs, Inc. | $2.17 | 5.66M | +13,775% | -66% | — | — | -1.08 | 0.26 | 18.70 | 3.47 | — | 0.26 | 96.53% | -8761.11% | -1727.78% | -35.31% | -1138.63% | -23.70% | 0.09 | -1261.60 | 3.25 | 3.04 | 4.69 | -9117.00% | 3211.00% | -3553.00% | -351.80% | -2.53 | -855.05% | 0.00% | 0.00% | 329.11% | 0.61 | 0.81 | -53.31 | -34.45 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
- CEO
- Tiago Reis Marques
- Employees
- 4
- Beta
- 0.21
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.84) − 1 = — (DCF, example).